Amgen Rebounds, Shaking Off 'Overdone' Fears Tied To Its Weight-Loss ShotInvestors Business Daily • 11/13/24
Amgen Drops 7% After A 'Big Unknown Risk' Rattles Its Monthly Obesity ShotInvestors Business Daily • 11/12/24
TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPSPRNewsWire • 11/08/24
Amgen Q3 Earnings Beat, Sales In Line, Obesity Candidate in FocusZacks Investment Research • 10/31/24
Compared to Estimates, Amgen (AMGN) Q3 Earnings: A Look at Key MetricsZacks Investment Research • 10/30/24
Amgen 'Laser-Focused' On Its Weight-Loss Shot As New Rival Pfizer Follows, Says CFOInvestors Business Daily • 10/30/24
Amgen Q3 Earnings Review: So Many Questions, But MariTide Data Top Of The ListSeeking Alpha • 10/25/24
Ahead of Amgen (AMGN) Q3 Earnings: Get Ready With Wall Street Estimates for Key MetricsZacks Investment Research • 10/25/24
Denosumab (Prolia & Xgeva) by Amgen Biosimilars Pipeline Review 2024: Drug Code/INN, Target(s)/MoA, Class of Compound, Territory of Main Competitor, Indication(s) & R&D StageGlobeNewsWire • 10/24/24
Amgen (AMGN) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseZacks Investment Research • 10/23/24
AMGEN PRESENTS POSITIVE PHASE 3 DATA FOR UPLIZNA® (INEBILIZUMAB-CDON) IN GENERALIZED MYASTHENIA GRAVIS (GMG) AT AANEM 2024PRNewsWire • 10/15/24